Jane Pei- Chen Chang, Shih-Sheng Chang, Hui-Ting Chen, Yu-Chuan Chien, Hui-Ting Yang, Shih-Yi Huang, Ping-Tao Tseng, Cheng-Ho Chang, Piotr Galecki & Kuan-Pin Su. (2023) Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs), Somatic and Fatigue Symptoms in Cardiovascular Diseases Comorbid Major Depressive Disorder (MDD): A Randomised Controlled Trial. Brain, Behavior, and Immunity.
Crossref
Lison Huet, Ines Delgado, Sandra Dexpert, Julie Sauvant, Bruno Aouizerate, Cédric Beau, Damien Forestier, Patrick Ledaguenel, Eric Magne & Lucile Capuron. (2021) Relationship between body mass index and neuropsychiatric symptoms: Evidence and inflammatory correlates. Brain, Behavior, and Immunity 94, pages 104-110.
Crossref
Karina Liubchenko, Kevin Kordbacheh, Nika Khajehdehi, Tanja Visnjevac, Frederick Ma, James S. Khan, Myles Storey, Alaa Abd-Elsayed & Ognjen Visnjevac. (2020) Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures. Advances in Therapy 38:2, pages 904-924.
Crossref
Susham Gupta, Olivia Fiertag, Thanakumar Thanulingam, Bryan Strange & James Warner. 2020. Clinical Topics in Old Age Psychiatry. Clinical Topics in Old Age Psychiatry
50
77
.
. 2020. Clinical Topics in Old Age Psychiatry. Clinical Topics in Old Age Psychiatry.
Chih Ying Lin, Ta-Wei Guu, Hsueh-Chou Lai, Cheng-Yuan Peng, Jill Yi-Ju Chiang, Hui-Ting Chen, Tsai-Chung Li, Shing-Yu Yang, Kuan-Pin Su & Jane Pei-Chen Chang. (2020) Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study. Brain, Behavior, & Immunity - Health 2, pages 100035.
Crossref
Nana Gletsu-Miller, Neeta Shevni, Amita Manatunga, Edward Lin & Dominique Musselman. (2019) A multidimensional analysis of the longitudinal effects of roux en y gastric bypass on fatigue: An association with visceral obesity. Physiology & Behavior 209, pages 112612.
Crossref
Kuan-Pin Su, Hsueh-Chou Lai, Cheng-Yuan Peng, Wen-Pang Su, Jane Pei-Chen Chang & Carmine M. Pariante. (2019) Interferon-alpha-induced depression: Comparisons between early- and late-onset subgroups and with patients with major depressive disorder. Brain, Behavior, and Immunity 80, pages 512-518.
Crossref
Dominique Musselman, Neeta Shenvi, Amita Manatunga, Andrew H. Miller, Edward Lin & Nana Gletsu-Miller. (2019) The effects of roux en y gastric bypass surgery on neurobehavioral symptom domains associated with severe obesity. Physiology & Behavior 204, pages 86-92.
Crossref
Giovanni Oriolo, Lison Huet, Sandra Dexpert, Cédric Beau, Damien Forestier, Patrick Ledaguenel, Eric Magne, Rocío Martin-Santos & Lucile Capuron. (2019) History of major depression is associated with neuropsychiatric symptoms but not systemic inflammation in a cross-sectional study in obese patients. Brain, Behavior, and Immunity 76, pages 215-222.
Crossref
Madeline Li, Ekaterina Kouzmina, Megan McCusker, Danielle Rodin, Paul C. Boutros, Christopher J. Paige & Gary Rodin. (2017) Pro- and anti-inflammatory cytokine associations with major depression in cancer patients. Psycho-Oncology 26:12, pages 2149-2156.
Crossref
David Mischoulon, Lindsay Hylek, Albert S. Yeung, Alisabet J. Clain, Lee Baer, Cristina Cusin, Dawn Flosnik Ionescu, Jonathan E. Alpert, David P. Soskin & Maurizio Fava. (2017) Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants. Journal of Affective Disorders 208, pages 6-14.
Crossref
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
17
24
.
. 2016. Meyler's Side Effects of Drugs. Meyler's Side Effects of Drugs
158
170
.
Susham Gupta & Erum Nomani. 2015. Diet and Nutrition in Dementia and Cognitive Decline. Diet and Nutrition in Dementia and Cognitive Decline
177
185
.
Kuan-Pin Su, Hsueh-Chou Lai, Hui-Ting Yang, Wen-Pang Su, Cheng-Yuan Peng, Jane Pei-Chen Chang, Hui-Chih Chang & Carmine M. Pariante. (2014) Omega-3 Fatty Acids in the Prevention of Interferon-Alpha-Induced Depression: Results from a Randomized, Controlled Trial. Biological Psychiatry 76:7, pages 559-566.
Crossref
Babita Ghai, Dipika Bansal, Debasish Hota & Chirag Shashikant Shah. (2014) Off-Label, Low-Dose Naltrexone for Refractory Chronic Low Back Pain. Pain Medicine 15:5, pages 883-884.
Crossref
Jennifer M. Loftis, Alexander L. Patterson, Clare J. Wilhelm, Henry McNett, Benjamin J. Morasco, Marilyn Huckans, Timothy Morgan, Shira Saperstein, Aliya Asghar & Peter Hauser. (2013) Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: A 16-week prospective study. Journal of Psychosomatic Research 74:1, pages 57-63.
Crossref
Susham Gupta, Olivia Fiertag, Thanakumar Thanulingam, Elena Ros, Bryan Strange & James Warner. (2018) Further rare and unusual dementias. Advances in Psychiatric Treatment 18:1, pages 67-77.
Crossref
Vellingiri Raja Badrakalimuthu, Daphne Rumball & Amit Chawla. (2018) Hepatitis C: a patient's journey from a psychiatrist's perspective. Advances in Psychiatric Treatment 17:5, pages 340-349.
Crossref
Lucile Capuron, Sebastian Schroecksnadel, Catherine Féart, Agnès Aubert, Denise Higueret, Pascale Barberger-Gateau, Sophie Layé & Dietmar Fuchs. (2011) Chronic Low-Grade Inflammation in Elderly Persons Is Associated with Altered Tryptophan and Tyrosine Metabolism: Role in Neuropsychiatric Symptoms. Biological Psychiatry 70:2, pages 175-182.
Crossref
Edward R Cachay, David L Wyles, Miguel Goicoechea, Francesca J Torriani, Craig Ballard, Bradford Colwell, Robert G Gish & William C Mathews. (2011) Reliability and predictive validity of a hepatitis-related symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. AIDS Research and Therapy 8:1, pages 29.
Crossref
Christina A. Meyers & Jeffrey S. Wefel. 2011. Cancer Symptom Science. Cancer Symptom Science
51
59
.
Mary T. RosedaleShiela M. Strauss. (2011) How Persons With Chronic Hepatitis C in Residential Substance Abuse Treatment Programs Think About Depression and Interferon Therapy. Journal of the American Psychiatric Nurses Association 16:6, pages 350-356.
Crossref
Benjamin J. Morasco, Jennifer M. Loftis, David W. Indest, Samantha Ruimy, John W. Davison, Bradford Felker & Peter Hauser. (2010) Prophylactic Antidepressant Treatment in Patients With Hepatitis C on Antiviral Therapy: A Double-Blind, Placebo-Controlled Trial. Psychosomatics 51:5, pages 401-408.
Crossref
John Onate. (2010) Use of Psychiatric Drugs in Patients With Hepatitis C Review and Recommendations. Psychopharm Review 45:3, pages 17-23.
Crossref
S. Freda Auyeung, Qi Long, Erica Bruce Royster, Smitha Murthy, Marcia D McNutt, David Lawson, Andrew Miller, Amita Manatunga & Dominique L Musselman. (2009) Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy. Clinical Trials 6:5, pages 480-490.
Crossref
Rosa Quelhas & Alice Lopes. (2009) Psychiatric Problems in Patients Infected with Hepatitis C Before and During Antiviral Treatment with Interferon-Alpha: A Review. Journal of Psychiatric Practice 15:4, pages 262-281.
Crossref
Jarred Younger & Sean Mackey. (2009) Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study. Pain Medicine 10:4, pages 663-672.
Crossref
J.-P. Lang, S. Schmitter, S. Benassi & L. Michel. (2009) Prise en charge de l'hépatite chronique C : une urgence psychiatrique ?. L'information psychiatrique 85:7, pages 629.
Crossref
Stéphane Schmitter, Jean-Philippe Lang, Laurent Michel & Laurent Castera. 2009. Psychiatrie, VIH et hépatite C. Psychiatrie, VIH et hépatite C
80
92
.
Jörg Dietrich, Michelle Monje, Jeffrey Wefel & Christina Meyers. (2008) Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy. The Oncologist 13:12, pages 1285-1295.
Crossref
Jeffrey S. Wefel, Robert Collins & Anne E. Kayl. 2009. Cognition and Cancer. Cognition and Cancer
97
114
.
Marc C. Chamberlain & Michael J. Glantz. (2008) Interferon‐α for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer 113:8, pages 2146-2151.
Crossref
Karin Gehring, Margriet M Sitskoorn, Neil K Aaronson & Martin JB Taphoorn. (2008) Interventions for cognitive deficits in adults with brain tumours. The Lancet Neurology 7:6, pages 548-560.
Crossref
Jeffrey S. Wefel, Mariana E. Witgert & Christina A. Meyers. (2008) Neuropsychological Sequelae of Non-Central Nervous System Cancer and Cancer Therapy. Neuropsychology Review 18:2, pages 121-131.
Crossref
Po-Lun Wu, Kuan-Fu Liao, Cheng-Yuan Peng, Carmine M. Pariante & Kuan-Pin Su. (2007) Manic episode associated with citalopram therapy for interferon-induced depression in a patient with chronic hepatitis C infection. General Hospital Psychiatry 29:4, pages 374-376.
Crossref
Jimmie C. Holland & Inga Reznik. (2005) Pathways for psychosocial care of cancer survivors. Cancer 104:S11, pages 2624-2637.
Crossref
Nachum Dafny & Pamela B. Yang. (2005) Interferon and the central nervous system. European Journal of Pharmacology 523:1-3, pages 1-15.
Crossref
Alan D. Valentine & Christina A. Meyers. (2005) Neurobehavioral effects of interferon therapy. Current Psychiatry Reports 7:5, pages 391-395.
Crossref
J. Vignau, L. Karila, O. Costisella & V. Canva. (2005) Hépatite C, Interféron α et dépression : principales hypothèses physiopathologiques. L'Encéphale 31:3, pages 349-357.
Crossref
Amber G. Paterson, Peter C. Trask, Lynne I. Wagner, Peg Esper & Bruce Redman. (2005) Validation of the FACT-BRM with interferon-α treated melanoma patients. Quality of Life Research 14:1, pages 133-139.
Crossref
Charles L Raison, Marina Demetrashvili, Lucile Capuron & Andrew H Miller. (2005) Neuropsychiatric Adverse Effects of Interferon-??. CNS Drugs 19:2, pages 105-123.
Crossref
Keizo Yoshida, Oyetunde Alagbe, Xiaohong Wang, Bobbi Woolwine, Marie Thornbury, Charles L. Raison & Andrew H. Miller. (2005) Promoter Polymorphisms of the Interferon-α Receptor Gene and Development of Interferon-Induced Depressive Symptoms in Patients with Chronic Hepatitis C: Preliminary Findings. Neuropsychobiology 52:2, pages 55-61.
Crossref
S. Hayley, M.O. Poulter, Z. Merali & H. Anisman. (2005) The pathogenesis of clinical depression: Stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 135:3, pages 659-678.
Crossref
Ian N. Johnston & R. Frederick Westbrook. (2005) Inhibition of morphine analgesia by LPS: role of opioid and NMDA receptors and spinal glia. Behavioural Brain Research 156:1, pages 75-83.
Crossref
Jennifer M. Loftis & Peter Hauser. (2004) The phenomenology and treatment of interferon-induced depression. Journal of Affective Disorders 82:2, pages 175-190.
Crossref
Peter C. Trask, Amber G. Paterson, Peg Esper, Jason Pau & Bruce Redman. (2003) Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psycho-Oncology 13:8, pages 526-536.
Crossref
Peter A. Gochee, Elizabeth E. Powell, David M. Purdie, Nirmala Pandeya, Livia Kelemen, Claudia Shorthouse, Julie R. Jonsson & Brian Kelly. (2004) Association Between Apolipoprotein E ɛ4 and Neuropsychiatric Symptoms During Interferon α Treatment for Chronic Hepatitis C. Psychosomatics 45:1, pages 49-57.
Crossref
Heinz Ludwig & Niklas Zojer. 2004. Biology and Management of Multiple Myeloma. Biology and Management of Multiple Myeloma
223
249
.
Elise A. Olsen. (2003) Interferon in the treatment of cutaneous T-cell lymphoma. Dermatologic Therapy 16:4, pages 311-321.
Crossref
Hope S Rugo & Tim Ahles. (2003) The impact of adjuvant therapy for breast cancer on cognitive function: current evidence and directions for research. Seminars in Oncology 30:6, pages 749-762.
Crossref
Alain H Rook, Timothy M Kuzel & Elise A Olsen. (2003) Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematology/Oncology Clinics of North America 17:6, pages 1435-1448.
Crossref
Lucile Capuron, Gabriele Neurauter, Dominique L Musselman, David H Lawson, Charles B Nemeroff, Dietmar Fuchs & Andrew H Miller. (2003) Interferon-alpha–induced changes in tryptophan metabolism. Biological Psychiatry 54:9, pages 906-914.
Crossref
Jennifer M Loftis & Peter Hauser. (2003) Comanagement of Depression and HCV Treatment. Psychiatric Annals 33:6, pages 385-391.
Crossref
John M. KirkwoodCatherine BenderSanjiv AgarwalaAhmad TarhiniJanice Shipe-SpotloeBarbara SmelkoSandra DonnellyLori Stover. (2002) Mechanisms and Management of Toxicities Associated With High-Dose Interferon Alfa-2b Therapy. Journal of Clinical Oncology 20:17, pages 3703-3718.
Crossref
Marc C. Chamberlain. (2002) A Phase II trial of intra‐cerebrospinal fluid alpha interferon in the treatment of neoplastic meningitis. Cancer 94:10, pages 2675-2680.
Crossref
Martin Schaefer, Marc A Engelbrechta, Oliver Gut, Bernd L Fiebich, Joachim Bauer, Folkhard Schmidt, Heinz Grunze & Klaus Lieb. (2002) Interferon alpha (IFNα) and psychiatric syndromes. Progress in Neuro-Psychopharmacology and Biological Psychiatry 26:4, pages 731-746.
Crossref
John P. Garofalo & Andrew Baum. (2001) Neurocognitive sequelae of cancer therapies. Current Opinion in Psychiatry 14:6, pages 575-583.
Crossref
SCOTT M. DINEHART, JAY KINCANNON & ROY GERONEMUS. (2001) Hemangiomas. Dermatologic Surgery 27:5, pages 475-485.
Crossref
Scott M. Dinehart, Jay Kincannon & Roy Geronemus. (2001) Hemangiomas: Evaluation and Treatment. Dermatologic Surgery 27:5, pages 475-485.
Crossref
Dominique L. Musselman, David H. Lawson, Jane F. Gumnick, Amita K. Manatunga, Suzanne Penna, Rebecca S. Goodkin, Kristen Greiner, Charles B. Nemeroff & Andrew H. Miller. (2001) Paroxetine for the Prevention of Depression Induced by High-Dose Interferon Alfa. New England Journal of Medicine 344:13, pages 961-966.
Crossref
Peter Hauser, Rosa Soler, Susan Reed, Robert Kane, Mangla Gulati, Jaswinder Khosla, Mitchel A. Kling, Alan D. Valentine & Christina A. Meyers. (2000) Prophylactic Treatment of Depression Induced by Interferon-α. Psychosomatics 41:5, pages 439-441.
Crossref
Peter C. TraskPeg EsperMichelle RibaBruce Redman. (2000) Psychiatric Side Effects of Interferon Therapy: Prevalence, Proposed Mechanisms, and Future Directions. Journal of Clinical Oncology 18:11, pages 2316-2326.
Crossref
Thierry Vial, Geneviève Choquet-Kastylevsky, Christine Liautard & Jacques Descotes. (2000) Endocrine and neurological adverse effects of the therapeutic interferons. Toxicology 142:3, pages 161-172.
Crossref
Christina A. Meyers. 1999. Cytokines, Stress, and Depression. Cytokines, Stress, and Depression
75
81
.
Pierre Triozzi & Robert Turowski. 1998. Cytokines. Cytokines.
. (1997) Reply. Journal of the American Academy of Dermatology 37:6, pages 1020-1021.
Crossref
Thierry Vial & Jacques Descotes. 1997.
326
362
.
A.H. Ghodse & R.E. Edwards. 1997.
76
85
.
Gayle A. Olson, Richard D. Olson & Abba J. Kastin. (1996) Endogenous opiates: 1995. Peptides 17:8, pages 1421-1466.
Crossref
P McLaughlin. (1996) The role of interferon in the therapy of malignant lymphoma. Biomedicine & Pharmacotherapy 50:3-4, pages 140-148.
Crossref